Page last updated: 2024-11-08

saponarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

saponarin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

7-O-(beta-D-glucosyl)isovitexin : A C-glycosyl compound that is isovitexin in which the hydroxyl hydrogen at position 7 is replaced by a beta-D-glucosyl residue. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441381
CHEMBL ID4640510
CHEBI ID75439
SCHEMBL ID2489122
MeSH IDM0428601

Synonyms (41)

Synonym
unii-3081z76ox9
isovitexin-7-o-glucoside
3081z76ox9 ,
4h-1-benzopyran-4-one, 3-((6-o-(6-deoxy-beta-l-mannofuranosyl)-beta-o-galactofuranosyl)oxy)-7-((6-deoxy-beta-l-mannopyranosyl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)-
saponaretin-7-o-glucoside
C08064
saponarin
20310-89-8
isovitexin-7-o-beta-d-glucopyranoside
isovitexin 7-o-glucoside
AC1L9B2G ,
5-hydroxy-2-(4-hydroxyphenyl)-6-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-7-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
CCG-208416
(1s)-1,5-anhydro-1-[7-(beta-d-glucopyranosyloxy)-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-6-yl]-d-glucitol
7-o-(beta-d-glucosyl)isovitexin
CHEBI:75439
6-.beta.-d-glucopyranosyl-7-(.beta.-d-glucopyranosyloxy)-5-hydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
isovitexin 7-.beta.-d-glucoside
saponarin [mi]
6-c-glucosyl-7-o-glucosylapigenin
isovitexin 7-glucoside
4h-1-benzopyran-4-one, 6-.beta.-d-glucopyranosyl-7-(.beta.-d-glucopyranosyloxy)-5-hydroxy-2-(4-hydroxyphenyl)-
isovitexin 7-.beta.-d-glucopyranoside
apigenin 6-c-glucosyl-7-o-glucoside
petrocomoside
7-o-glucosylisovitexin
mfcd00238679
SCHEMBL2489122
HGUVPEBGCAVWID-KETMJRJWSA-N
5-hydroxy-2-(4-hydroxyphenyl)-6-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]-7-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one
DTXSID10174201
SR-05000002259-2
sr-05000002259
5-hydroxy-2-(4-hydroxyphenyl)-6-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)-7-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-4h-chromen-4-one
AKOS037514829
Q63408652
5-hydroxy-2-(4-hydroxyphenyl)-6-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
CS-0032401
MS-30560
HY-N5083
CHEMBL4640510

Research Excerpts

Treatment

Saponarin pretreatment resulted in significant increase in cell antioxidant defence system and GSH levels. Treatment with saponarin ameliorated the above mentioned liver parameters in both diabetic strains. Its effects were less pronounced in the diabetic SHR group.

ExcerptReferenceRelevance
"Saponarin pretreatment resulted in significant increase in cell antioxidant defence system and GSH levels and decrease in lipid peroxidation."( Hepatoprotective and antioxidant effects of saponarin, isolated from Gypsophila trichotoma Wend. on paracetamol-induced liver damage in rats.
Kondeva-Burdina, M; Krasteva, I; Manov, V; Mitcheva, M; Simeonova, R; Vitcheva, V, 2013
)
1.37
"Saponarin pretreatment, however, decreased cocaine toxicity both by increasing GSH levels and antioxidant enzyme activities."( Hepatoprotective effects of saponarin, isolated from Gypsophila trichotoma Wend. on cocaine-induced oxidative stress in rats.
Krasteva, I; Mitcheva, M; Nikolov, S; Simeonova, R; Vitcheva, V; Yotova, M, 2011
)
1.38
"Treatment with saponarin ameliorated the above mentioned liver parameters in both diabetic strains, however its effects were less pronounced in the diabetic SHR group."( Antidiabetic and antioxidant effects of saponarin from Gypsophila trichotoma on streptozotocin-induced diabetic normotensive and hypertensive rats.
Ionkova, I; Konstantinov, S; Krasteva, I; Simeonova, R; Vitcheva, V; Zdraveva, P, 2016
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
C-glycosyl compoundA glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond.
dihydroxyflavoneAny hydroxyflavone in which two ring hydrogens are replaced by hydroxy substituents.
glycosyloxyflavoneA member of the class of flavones having one or more glycosyl residues attached at unspecified positions.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
isovitexin glycosides biosynthesis025

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1659751Agonist activity at TRPA1 (unknown origin) at 1000 uM relative to AITC2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Identification of a new class of non-electrophilic TRPA1 agonists by a structure-based virtual screening approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.00)18.7374
1990's0 (0.00)18.2507
2000's3 (12.00)29.6817
2010's16 (64.00)24.3611
2020's5 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.00 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]